Last updated 18 days ago
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
140 patients around the world
Available in Mexico, United States
Eli Lilly and Company
8Research sites
140Patients around the world
This study is for people with
Obesity
Renal disease
Chronic kidney disease
Diabetes
Diabetes mellitus type 2
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- All participants with or without diabetes: Have a Body Mass Index (BMI) ≥27 kilogram/square meter (kg/m²) at screeningAll participants with or without diabetes: Diagnosed with chronic kidney disease (CKD)All participants with or without diabetes: Has an estimated glomerular filtration rate (eGFR) ≥30 to ≤60 ml/min/1.73 m² or eGFR ≥30 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (UACR) >30 milligram/gram (mg/g)All participants with or without diabetes: Have been receiving an angiotensin-converting enzyme (ACE) or angiotensin II receptor blockers (ARB) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension)Participants without diabetes: Have Hemoglobin A1c (HbA1c) <6.5% at screeningParticipants with Type 2 diabetes: Have been diagnosed at least 180 days prior to screeningParticipants with Type 2 diabetes: Have HbA1c ≥7.0% to ≤10.5% at screening
- All participants: Have a self-reported change in body weight >5 kilogram (kg) within 90 days prior to screening.All participants: Have a prior or planned surgical treatment for obesityAll participants: Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 daysAll participants: Have eGFR <30 mL/min/1.73m² calculated by using creatinine-based chronic kidney disease epidemiology collaboration (CKD-EPI) equations, as determined by central laboratory at screening.All participants: Have a history of unstable or rapidly progressing renal disease according to investigator judgmentAll participants: Have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility)All participants: Have had a history of chronic or acute pancreatitisParticipants with T2D: Have history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment.Participants with T2D: Have been diagnosed with type 1 diabetes (T1D) or have history of ketoacidosis or hyperosmolar state/coma
Sites
Instituto Nacional de Ciencias Médicas y Nutrición Dr. Salvador Zubirán
Recruiting
CAIMED - Investigación en salud S.A de C.V. - México
Recruiting
AGNI Research and Assessment S.C.
Recruiting
Centro de Investigación y Gastroenterología
Recruiting
Instituto Nacional de Cardiologia Ignacio Chavez
Recruiting
Health Pharma Professional Research
Recruiting
Grupo Médico Camino S.C. - Mexico
Recruiting
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas
Recruiting
StudyTREASURE-CKD
SponsorEli Lilly and Company
Study typeInterventional
Conditions
ObesityChronic kidney diseaseDiabetes mellitus type 2
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05536804
